This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.

Aichi Cancer Center Hospital Nagoya Japan

American University of Beirut Beirut Lebanon

BC Cancer University of British Columbia Vancouver Canada

Clinic Favoriten HPB Center Health Network Vienna and Sigmund Freud University Medical School Vienna Austria

Clinica Universidad de Navarra and CIBEREHD Pamplona Spain

Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Oncology OncoHealth Institute Fundación Jiménez Díaz University Hospital Madrid Spain; Department of Medical Oncology The Christie NHS Foundation Manchester; Division of Cancer Sciences University of Manchester Manchester UK

Hammersmith Hospital Imperial College London London UK

Henry Ford Cancer Institute Departments of Oncology and Pharmacology Wayne State University Detroit USA

Icahn School of Medicine at Mount Sinai Mount Sinai Liver Cancer Program New York USA; Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic Universitat de Barcelona Barcelona; Institució Catalana de Recerca i Estudis Avançats Barcelona Spain

INCLIVA Biomedical Research Institute Hospital Clínico Universitario University of Valencia Valencia Spain

Institut du cancer Paris CARPEM APHP Georges Pompidou Hospital Université Paris Cité Paris France

Instituto Alexander Fleming Buenos Aires Argentina

Instituto Nacional de Cancerologia Mexico Mexico

Karolinska University Hospital Karolinska Institutet Stockholm Sweden; Tampere University Hospital University of Tampere Tampere Finland

Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University Brno Czech Republic

Mayo Clinic Cancer Center Phoenix

Memorial Sloan Kettering Cancer Center New York; Weill Cornell College of Medicine New York USA

Memorial Sloan Kettering Cancer Center New York; Weill Cornell College of Medicine New York USA; Trinity College Dublin Dublin Ireland

Ulm University Hospital Ulm Germany

Université Paris Saclay Gustave Roussy Villejuif France

University Hospitals Gasthuisbergs Leuven; Katholieke Universiteit Leuven Leuven Belgium

University Medical Center Mainz Mainz Germany

University of Leipzig Medical Center Comprehensive Cancer Center Central Germany Leipzig Germany

Vall d'Hebron Hospital Campus and Institute of Oncology IOB Quiron UVic UCC Barcelona Spain

Vall d'Hebron Hospital Campus Barcelona Spain; Institute of Oncology IOB Quiron UVic UCC Barcelona Spain

Vanderbilt Ingram Cancer Center Nashville USA

Zobrazit více v PubMed

Rumgay H., Arnold M., Ferlay J., et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–1606. PubMed PMC

Rumgay H., Ferlay J., de Martel C., et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108–118. PubMed

Balogh J., Victor D., 3rd, Asham E.H., et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53. PubMed PMC

Llovet J.M., Kelley R.K., Villanueva A., et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. PubMed

Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33. PubMed

Wong G.L., Hui V.W., Yip T.C., et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2022;56:869–877. PubMed

Younossi Z., Stepanova M., Ong J.P., et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17:748–755 e743. PubMed

European Association for the Study of the Liver Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. PubMed

Tzartzeva K., Obi J., Rich N.E., et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154:1706–1718.e1701. PubMed PMC

Gupta P., Soundararajan R., Patel A., Kumar M.P., Sharma V., Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J Hepatol. 2021;75:108–119. PubMed

Pelizzaro F., Peserico G., D'Elia M., et al. Surveillance for hepatocellular carcinoma with a 3-months interval in ‘extremely high-risk’ patients does not further improve survival. Dig Liver Dis. 2022;54:927–936. PubMed

Kansagara D., Papak J., Pasha A.S., et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014;161:261–269. PubMed

Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649. PubMed

Child C.G., Turcotte J.G. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85. PubMed

Johnson P.J., Berhane S., Kagebayashi C., et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–558. PubMed PMC

Fulgenzi C.A.M., Cheon J., D’Alessio A., et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study. Eur J Cancer. 2022;175:204–213. PubMed

Vogel A., Chan S., Furuse J., et al. O5—Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study. Ann Oncol. 2022;33:S380–S381.

Kudo M., Galle P.R., Brandi G., et al. Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and REACH-2. JHEP Rep. 2021;3 PubMed PMC

ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC) https://www.mdcalc.com/calc/10070/albi-albumin-bilirubin-grade-hepatocellular-carcinoma-hcc Available at.

Kariyama K., Nouso K., Hiraoka A., et al. EZ-ALBI score for predicting hepatocellular carcinoma prognosis. Liver Cancer. 2020;9:734–743. PubMed PMC

Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470. PubMed

Kim W.R., Biggins S.W., Kremers W.K., et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–1026. PubMed PMC

Reig M., Forner A., Rimola J., et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–693. PubMed PMC

Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338. PubMed

Kudo M., Chung H., Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) J Gastroenterol. 2003;38:207–215. PubMed

Ayuso C., Rimola J., Vilana R., et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72–81. PubMed

Chernyak V., Tang A., Do R.K.G., et al. Liver imaging: it is time to adopt standardized terminology. Eur Radiol. 2022;32:6291–6301. PubMed

Bhagat V., Javle M., Yu J., et al. Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer. 2006;37:27–34. PubMed

Wachtel M.S., Zhang Y., Xu T., et al. Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol. 2008;1:43–47. PubMed PMC

Harding J.J., Nandakumar S., Armenia J., et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25:2116–2126. PubMed PMC

Marrero J.A., Kulik L.M., Sirlin C.B., et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68:723–750. PubMed

Kim K., Kim S.J. Diagnostic test accuracies of F-18 FDG PET/CT for prediction of microvascular invasion of hepatocellular carcinoma: a meta-analysis. Clin Imaging. 2021;79:251–258. PubMed

Chotipanich C., Kunawudhi A., Promteangtrong C., et al. Diagnosis of hepatocellular carcinoma using C11 choline PET/CT: comparison with F18 FDG, contrast enhanced MRI and MDCT. Asian Pac J Cancer Prev. 2016;17:3569–3573. PubMed

Vidili G., Arru M., Solinas G., et al. Contrast-enhanced ultrasound liver imaging reporting and data system: lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis. World J Gastroenterol. 2022;28:3488–3502. PubMed PMC

Lefrere J.J., Gozin D., Soulier J.P., et al. Specificity of increased des-gamma-carboxyprothrombin in hepatocellular carcinoma after vitamin K1 injection. J Hepatol. 1987;5:27–29. PubMed

Kabir T., Tan Z.Z., Syn N.L., et al. Laparoscopic versus open resection of hepatocellular carcinoma in patients with cirrhosis: meta-analysis. Br J Surg. 2021;109:21–29. PubMed

Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699. PubMed

Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403. PubMed

Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43. PubMed

Duvoux C., Roudot-Thoraval F., Decaens T., et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–994 e983. quiz e914-985. PubMed

Pinero F., Tisi Bana M., de Ataide E.C., et al. Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int. 2016;36:1657–1667. PubMed

Llovet J.M., De Baere T., Kulik L., et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293–313. PubMed

Di Martino M., Vitale A., Ferraro D., et al. Downstaging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis on intention-to-treat outcomes. Cancers (Basel) 2022;14:5102. PubMed PMC

Takayama T., Hasegawa K., Izumi N., et al. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial) Liver Cancer. 2022;11:209–218. PubMed PMC

Dou Z., Lu F., Ren L., et al. Efficacy and safety of microwave ablation and radiofrequency ablation in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore) 2022;101 PubMed PMC

Salem R., Johnson G.E., Kim E., et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342–2352. PubMed PMC

Lee J., Shin I.S., Yoon W.S., Koom W.S., Rim C.H. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother Oncol. 2020;145:63–70. PubMed

Rim C.H., Lee J.S., Kim S.Y., Seong J. Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: a hybrid meta-analysis. JHEP Rep. 2023;5 PubMed PMC

Vogel A., Cervantes A., Chau I., et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238–iv255. PubMed

Vogel A., Martinelli E., ESMO Guidelines Committee Electronic address: clinicalguidelines@esmo.org; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32:801–805. PubMed

Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442. PubMed

Brown K.T., Do R.K., Gonen M., et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34:2046–2053. PubMed PMC

Garin E., Tselikas L., Guiu B., et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17–29. PubMed

Brown A.M., Kassab I., Massani M., et al. TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis. Cancer Med. 2023;12:2590–2599. PubMed PMC

Dhondt E., Lambert B., Hermie L., et al. (90)Y Radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303:699–710. PubMed

Li Q.J., He M.K., Chen H.W., et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40:150–160. PubMed

Kudo M., Ueshima K., Ikeda M., et al. Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma. Liver Cancer. 2022;11:354–367. PubMed PMC

Buckstein M., Kim E., Ozbek U., et al. Combination transarterial chemoembolization and stereotactic body radiation therapy for unresectable single large hepatocellular carcinoma: results from a prospective phase 2 trial. Int J Radiat Oncol Biol Phys. 2022;114:221–230. PubMed

Peng Z.W., Zhang Y.J., Chen M.S., et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426–432. PubMed

Wang X., Hu Y., Ren M., et al. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol. 2016;17:93–102. PubMed PMC

Comito T., Loi M., Franzese C., et al. Stereotactic radiotherapy after incomplete transarterial (chemo-) embolization (TAE∖TACE) versus exclusive TAE or TACE for treatment of inoperable HCC: a phase III trial (NCT02323360) Curr Oncol. 2022;29:8802–8813. PubMed PMC

Mo A., Velten C., Jiang J.M., et al. Improving adjuvant liver-directed treatment recommendations for unresectable hepatocellular carcinoma: an artificial intelligence-based decision-making tool. JCO Clin Cancer Inform. 2022;6 PubMed PMC

Finn R.S., Qin S., Ikeda M., et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. PubMed

Abou-Alfa G.K., Chan S.L., Kudo M., et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40:379.

Rimassa L., Personeni N., Czauderna C., Foerster F., Galle P. Systemic treatment of HCC in special populations. J Hepatol. 2021;74:931–943. PubMed

Carroll R.P., Boyer M., Gebski V., et al. Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study. Lancet Oncol. 2022;23:1078–1086. PubMed

Finn R.S., Ryoo B.Y., Merle P., et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193–202. PubMed

Abou-Alfa G.K., Borgman-Hagey A.E., Kelley R.K. Cabozantinib in hepatocellular carcinoma. N Engl J Med. 2018;379:1384–1385. PubMed

Qin S., Chen Z., Fang W., et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial. J Clin Oncol. 2023;41:1434–1443. PubMed PMC

Yau T., Kang Y.K., Kim T.Y., et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6 PubMed PMC

Bruix J., Qin S., Merle P., et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66. PubMed

Zhu A.X., Kang Y.K., Yen C.J., et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–296. PubMed

Bruix J., Chan S.L., Galle P.R., Rimassa L., Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75:960–974. PubMed

Storandt M.H., Gile J.J., Palmer M.E., et al. Cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma. Cancers (Basel) 2022;14:5173. PubMed PMC

Shui Y., Yu W., Ren X., et al. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol. 2018;13:188. PubMed PMC

He M., Li Q., Zou R., et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5:953–960. PubMed PMC

Chow P., Chen M., Cheng A.L., et al. AACR; Orlando, Florida. Philadelphia, PA: 2023. IMbrave050: phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. Proceedings of the 114th Annual Meeting of the American Association for Cancer Research. April 14-19, 2023; p. CT003.

Peng Z., Fan W., Zhu B., et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH) J Clin Oncol. 2023;41:117–127. PubMed

Dawson L.A., Winter K.A., Knox J.J., et al. NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) J Clin Oncol. 2023;41:489.

Qin S., Kudo M., Meyer T., et al. Final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Ann Oncol. 2022;33:S808–S809. PubMed

Qin S., Chan L.S., Gu S., et al. Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann Oncol. 2022;33:LBA35.